Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Replimune Group (REPL – Research Report), Capricor Therapeutics (CAPR – Research Report) and Intellia Therapeutics (NTLA – Research Report).
Replimune Group (REPL)
BTIG analyst Kaveri Pohlman maintained a Buy rating on Replimune Group yesterday and set a price target of $60.00. The company’s shares closed last Tuesday at $16.18, close to its 52-week low of $15.40.
According to TipRanks.com, Pohlman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Replimune Group with a $53.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Capricor Therapeutics (CAPR)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics, with a price target of $40.00. The company’s shares closed last Tuesday at $2.90, close to its 52-week low of $2.78.
According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Capricor Therapeutics is a Moderate Buy with an average price target of $26.00, implying a 755.3% upside from current levels. In a report issued on October 2, Maxim Group also reiterated a Buy rating on the stock with a $12.00 price target.
Intellia Therapeutics (NTLA)
Citi analyst David Lebovitz maintained a Hold rating on Intellia Therapeutics yesterday and set a price target of $40.00. The company’s shares closed last Tuesday at $29.68, close to its 52-week low of $28.78.
According to TipRanks.com, Lebovitz is a 1-star analyst with an average return of
Currently, the analyst consensus on Intellia Therapeutics is a Strong Buy with an average price target of $75.69.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REPL:
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Replimune Group price target lowered to $50 from $51 at H.C. Wainwright
- Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
- Replimune Group expects cash to fund operations into 2H25
- Replimune Group reports Q1 EPS (75c), consensus (85c)
